Mounjaro and tirzepatide injuries
Tirzepatide is a dual GLP-1/GIP receptor agonist. Like semaglutide it dramatically slows gastric emptying and shares a similar adverse-event profile. Eli Lilly is now named alongside Novo Nordisk in MDL 3094.
Do you qualify?
If you took Mounjaro and were diagnosed with a qualifying injury (gastroparesis, severe pancreatitis, intestinal obstruction, gallbladder disease, vision loss, or aspiration), you may have a claim.